Search InvestCenter

Recent Quotes

My Watchlist

Top Indices

Articles published by Acrivon Therapeutics, Inc

< Previous 1 2 Next >

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

March 05, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

March 04, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

February 27, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

February 08, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 06, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

January 03, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer

November 28, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

November 21, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

November 09, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 16, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 28, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on

September 19, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

September 05, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Participate in Two Investor Conferences in September

August 30, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 11, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs

July 20, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

June 22, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

June 02, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer

May 09, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 09, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

April 25, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023

April 24, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

April 18, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 28, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 06, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference

February 27, 2023

From Acrivon Therapeutics, Inc

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.